Dehaier Medical Signed an Exclusive Distribution Agreement with GCE Group, Europe’s Leading Gas-equipment Company

BEIJING, Sept. 28, 2012 /PRNewswire-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has signed a two-year distribution agreement with GCE group, a leading global compressed gas-equipment company, to become the exclusive distributor for GCE’s EASE II products in Mainland China.

(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO)

EASE II is an automatically triggered high-flow oxygen device, which can be connected with a portable oxygen tank or medical gas pipeline system to deliver high flows of oxygen to patients with minimal breathing resistance. The device can also benefit patients with sudden cardiac vascular disease, gas poisoning and other patients who require oxygen therapy. In certain emergency situations, EASE II helps to save lives by effectively increasing the degree of blood oxygen saturation and accelerating the recovery of cell functions when patients experience severe hypoxia.

In addition, the EASE II system can be used to deliver nitrous oxide-oxygen on demand to administer effective pain relief for a wide range of medical situations, such as accidents, medical surgery, skin burns, and various sports injuries. The product, distinguished by its portability and easy use, has been widely used in many fields including disaster relief efforts, national defense, emergency rooms, ambulances, and medical institutions around the world.

Dehaier’s President and CEO, Mr. Ping Chen, stated, “We are excited to be the exclusive distributor of EASE II in China and plan to occupy the immature market of high-efficiency oxygen in China with the GCE Group. Furthermore, Dehaier will begin to promote this efficient and state of the art emergency care concept and its related products by working closely with hospital specialists, as well as participating in academic seminars on emergency care and oxygen therapy. We believe that the EASE II concept and its application have a great market potential in the China’s growing medical equipment market, and going forward, we hope that EASE II system will be an important revenue contributors to Dehaier. ”

About GCE Group

The GCE Group is Europe’s leading gas-equipment company and organized according to four business areas: Cutting and Welding, Medical, High-Purity and Process Applications. Backed by Argan Capital Advisors LLP, a leading independent private equity fund focused on acquiring European mid-market companies, GCE’s product portfolio corresponds to a large variety of applications, from simple pressure regulators and blowpipes for cutting and welding to sophisticated gas supply systems for medical and electronics industry applications. GCE’s portfolio includes a large number of brands such as Butbro, Charledave, DruVa, Mediline, Mujelli, Propaline, Rhona and Sabre Medical, which are leaders within their own respective regional markets and applications. The GCE Group has grown rapidly since its establishment and is leading the restructuring of the European gas-equipment industry through mergers and acquisitions. The group currently employs approximately 1,100 people.

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the exclusive distribution agreement of EASE II. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn

Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn